,111 Recently, in patients with extensive-stage SCLC, compounding innovative Chinese PD-L1 mAb, adebrelimab, with EP chemotherapy has also shown better efficacy than EP chemotherapy alone, extending OS (15.3 vs. 12.8 months, HR = 0.72, P = 0.0017) and PFS (5.8 vs. 5.6 months, HR = 0.67, P < 0.0001) and yielding manageable toxicity.112. The gene discussed is CD274; the disease is small cell lung carcinoma.